AMH Test Shows Egg Reserve, But Not Fertility Timeline

Anti-Mullerian hormone, or AMH, has gained prominence as a biomarker for assessing ovarian reserve—the total pool of remaining eggs available for reproduction. The hormone is produced by small follicles in the ovaries and circulates in the bloodstream at measurable levels that correlate with egg quantity. For this reason, AMH testing has become increasingly popular among women in India and across South Asia who wish to understand their fertility status.

However, fertility specialists emphasise that AMH testing reveals information about egg supply rather than predicting how many years of fertility a woman has remaining. While higher AMH levels generally suggest a larger pool of eggs, the test does not account for egg quality, which naturally declines with age and significantly affects the likelihood of successful conception and healthy pregnancy. A woman with high AMH may still face challenges conceiving if her eggs are of poor quality, while another with lower AMH might achieve pregnancy more readily.

Fertility experts stress that AMH should be interpreted alongside other clinical factors including age, menstrual history, and results from other tests such as follicle-stimulating hormone levels and ultrasound imaging of the ovaries. The test provides a snapshot of ovarian reserve at a single point in time and does not account for individual variation in egg loss or aging processes. Some women experience rapid declines in AMH, while others see minimal changes over years.

For women considering family planning decisions in India, medical professionals recommend viewing AMH as one informative tool rather than a definitive measure of remaining reproductive years. Consulting with a qualified fertility specialist who can contextualise AMH results within a woman's complete medical picture remains the most reliable approach to understanding individual fertility prospects and making informed decisions about timing and family planning options.